Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry.

Okano M, Sato M, Ikekita A, Kageyama S

Rapid communications in mass spectrometry : RCM1 Jul 2010Cited by 45 (Europe PMC)

PMID20552695DOI10.1002/rcm.4619PepBankPUB-20552695

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. 1 result from people.

01HumanNon-randomized trialPharmacokinetics
In ten male volunteers given intravenous GHRP‑2, unchanged GHRP‑2 and its metabolite AA-3 were detected in urine in all ten cases.
In plain wordsIn ten men given GHRP‑2 by vein, the unchanged peptide and its breakdown product were found in urine in every case.
Peptide
GHRP-2
Outcome
Not applicableUrinary detection of unchanged GHRP-2 after intravenous dose
Study
n = 10
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · intravenousAs given in this study (human).
Source sentences
Summary
In all ten cases, unchanged GHRP-2 and its specific metabolite AA-3 were detected in urine.
2 context sentences(design, population, supporting numbers)
Summary · context
Intravenous administration of GHRP-2 in ten male volunteers was studied to demonstrate the applicability of the method.
Summary · context
Therefore, the mass spectrometric identification of urinary GHRP-2 and its metabolite D-Ala-D-(beta-naphthyl)-Ala-Ala-OH (AA-3) was studied using liquid chromatography/electrospray ionization tandem mass spectrometry for doping control purposes.
Report a problemFND-2055269505

Studies that did not test the peptide alone4

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

02LabNot a test of GHRP-2 aloneIn vitro (cell-free)Other
An LC-MS/MS method determined GHRP‑2 and its metabolite AA-3 at urinary concentrations of 0.5-10 ng/mL.
In plain wordsIn lab tests, a mass-spectrometry method measured GHRP‑2 and its breakdown product in urine at 0.5-10 ng/mL.
Peptide
GHRP-2
Outcome
Not applicableUrinary concentration range of the LC-MS/MS assay
Study
n: not reported in source
Human urine, LC-MS/MS assay
Outcome group
Pharmacokinetics · Pharmacology
Measurements
Urinary concentration range
0.5 to 10 ng/mL
GHRP-2 and AA-3
Source sentences
Summary
and the two target peptides were determined at urinary concentrations of 0.5-10 ng/mL.
1 context sentence(design, population, supporting numbers)
Summary · context
Therefore, the mass spectrometric identification of urinary GHRP-2 and its metabolite D-Ala-D-(beta-naphthyl)-Ala-Ala-OH (AA-3) was studied using liquid chromatography/electrospray ionization tandem mass spectrometry for doping control purposes.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-2055269501
03LabNot a test of GHRP-2 aloneIn vitro (cell-free)Other
The LC-MS/MS method recovered GHRP‑2 and AA-3 from urine at 84 to 101%.
In plain wordsIn lab tests, the urine method recovered between 84 and 101% of GHRP‑2 and its breakdown product.
Peptide
GHRP-2
Outcome
Not applicableAssay recovery
Study
n: not reported in source
Human urine, LC-MS/MS assay
Outcome group
Pharmacokinetics · Pharmacology
Measurements
Recovery
84 to 101%
GHRP-2 and AA-3
Source sentences
Summary
The recoveries ranged from 84 to 101%
1 context sentence(design, population, supporting numbers)
Summary · context
Therefore, the mass spectrometric identification of urinary GHRP-2 and its metabolite D-Ala-D-(beta-naphthyl)-Ala-Ala-OH (AA-3) was studied using liquid chromatography/electrospray ionization tandem mass spectrometry for doping control purposes.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-2055269502
04LabNot a test of GHRP-2 aloneIn vitro (cell-free)Other
The LC-MS/MS method had intra-day precision of 1.6-3.8%.
In plain wordsIn lab tests, repeat measurements on the same day of GHRP‑2 in urine agreed within 1.6-3.8%.
Peptide
GHRP-2
Outcome
Not applicableAssay intra-day precision
Study
n: not reported in source
Human urine, LC-MS/MS assay
Outcome group
Pharmacokinetics · Pharmacology
Measurements
Intra-day precision
1.6 to 3.8%
GHRP-2 and AA-3
Source sentences
Summary
the assay precisions were calculated as 1.6-3.8% (intra-day) and 1.9-4.3% (inter-day).
1 context sentence(design, population, supporting numbers)
Summary · context
Therefore, the mass spectrometric identification of urinary GHRP-2 and its metabolite D-Ala-D-(beta-naphthyl)-Ala-Ala-OH (AA-3) was studied using liquid chromatography/electrospray ionization tandem mass spectrometry for doping control purposes.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-2055269503
05LabNot a test of GHRP-2 aloneIn vitro (cell-free)Other
The LC-MS/MS method had inter-day precision of 1.9-4.3%.
In plain wordsIn lab tests, repeat measurements of GHRP‑2 in urine on different days agreed within 1.9-4.3%.
Peptide
GHRP-2
Outcome
Not applicableAssay inter-day precision
Study
n: not reported in source
Human urine, LC-MS/MS assay
Outcome group
Pharmacokinetics · Pharmacology
Measurements
Inter-day precision
1.9 to 4.3%
GHRP-2 and AA-3
Source sentences
Summary
the assay precisions were calculated as 1.6-3.8% (intra-day) and 1.9-4.3% (inter-day).
1 context sentence(design, population, supporting numbers)
Summary · context
Therefore, the mass spectrometric identification of urinary GHRP-2 and its metabolite D-Ala-D-(beta-naphthyl)-Ala-Ala-OH (AA-3) was studied using liquid chromatography/electrospray ionization tandem mass spectrometry for doping control purposes.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-2055269504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.